Nureca Limited Reports 87% Growth for Q4 FY25, Expands Reach with Swiggy and Release Strategic Priorities for FY 26

Export Growth: Leverage US FDA certifications to expand into North American and Middle Eastern markets. I would like to take this opportunity to express my gratitude to our shareholders for their continued confidence in Nureca. We are excited about the opportunities that lie ahead and are committed to delivering strong results in the coming quarters.